# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K191562   
B Applicant Horiba ABX SAS

C Proprietary and Established Names Yumizen C1200 Ferritin, Yumizen C1200 Transferrin, Yumizen C1200 Rheumatoid Factor

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DBF</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5340 -Ferritin ImmunologicalTest System</td><td rowspan=1 colspan=1>IM - Immunology</td></tr><tr><td rowspan=1 colspan=1>DDG</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5880 -Transferrin immunologicaltest system</td><td rowspan=1 colspan=1>IM - Immunology</td></tr><tr><td rowspan=1 colspan=1>DHR</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5775 -Rheumatoid factorimmunological test system</td><td rowspan=1 colspan=1>IM - Immunology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New assays

B Measurand: Ferritin Transferrin Rheumatoid Factor (RF)

C Type of Test: Quantitative immunoturbidmetric assays

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

Yumizen C1200 Ferritin reagent is intended for the quantitative in vitro diagnostic determination of ferritin in human serum by latex-enhanced immunoturbidimetric assay. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, hemochromatosis (iron overload), and iron deficiency anemia.

Yumizen C1200 Transferrin reagent is intended for the quantitative in vitro diagnostic determination of transferrin in human serum and lithium heparin plasma by turbidimetry. Measurement of transferrin levels aids in the diagnosis of malnutrition, acute inflammation, infection, and iron deficiency anemia.

Yumizen C1200 Rheumatoid Factor reagent is intended for the quantitative in vitro diagnostic determination of rheumatoid factor in human serum by latex-enhanced immunoturbidimetric assay. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements: For the Yumizen C1200 (K183375 and K191993) only

# IV Device/System Characteristics:

# A Device Description:

Yumizen C1200 Ferritin:

Reagent 1: Glycine buffer solution Reagent 2: Suspension of latex particles bound to rabbit anti-ferritin antibodies

Yumizen C1200 Transferrin:

Reagent 1: TRIS buffer solution Reagent 2: Goat anti-human transferrin antibodies in TRIS buffer

Yumizen C1200 Rheumatoid Factor:

• Reagent 1: Glycine buffer solution Reagent 2: Suspension of latex particles sensitized with denatured human IgG

All assays’ calibrators and control materials are sold separately.

# B Principle of Operation:

Yumizen C1200 Ferritin:

When an antigen-antibody reaction occurs between ferritin in a sample and rabbit anti-ferritinantibodies coated on latex particles, agglutination results. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of ferritin in the sample. The actual concentration is calculated from a calibration curve.

Immune complexes formed in solution scatter light in proportion to their size, shape, and concentration. Turbidimeters measure the reduction of incidence light due to reflection, absorption or scatter. In this procedure, the measurement of the rate of decrease in light intensity transmitted (increase in absorbance) through particles suspended in solution is the result of complexes formed during the immunological reaction between the analyte in the patient sample and rabbit anti-ferritin-antibodies coated on latex particles.

# Yumizen C1200 Transferrin:

The immunoturbidimetric assay measures increasing sample turbidity caused by the formation of insoluble immune complexes when goat anti-human transferrin antibodies are bound to added to the transferrin sample in the sample. The transferrin concentration is proportional to the amount of turbidity formed.

# Yumizen C1200 Rheumatoid Factor:

When an antigen-antibody reaction occurs between RF in a sample and denatured human IgG which has been attached to latex particles, agglutination results. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of RF in the sample. The actual concentration is calculated from a calibration curve.

# V Substantial Equivalence Information:

A Predicate Device Name(s):Beckman Coulter Ferritin Reagent, Model: OSR61203 Roche TINA-QUANT TRANSFERRIN VER.2 Olympus RF Latex Reagent

B Predicate 510(k) Number(s): K092505 K012393 K060201

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">DeviceK191562</td><td colspan="1" rowspan="1">PredicateK092505</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Yumizen C1200 Ferritin</td><td colspan="1" rowspan="1">Beckman Coulter FerritinReagent, Model: OSR61203</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications forUse</td><td colspan="1" rowspan="1">Yumizen C1200 Ferritin reagent isintended for the quantitative invitro diagnostic determination offerritin in human serum by latex-enhanced immunoturbidimetric</td><td colspan="1" rowspan="1">The Ferritin Reagent is for thedetermination of ferritinconcentrations in human serumand plasma on the BeckmanCoulter family of clinical</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">assay. Measurements of ferritinaid in the diagnosis of diseasesaffecting iron metabolism,hemochromatosis (iron overload)and iron deficiency anemia.</td><td colspan="1" rowspan="1">chemistry analyzers. Serumferritin is an indicator of body ironstores: it has been shown tocorrelate with stainable bonemarrow iron. Measurements offerritin aid in the diagnosis ofdiseases affecting ironmetabolism, such ashemochromatosis (iron overload)and iron deficiency anemia.</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Latex enhanced immuno-turbidimetry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Quantitative, competitive</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">3rd International Standard forFerritin, Recombinant NIBSCCode: 94/572</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General Device C</td><td colspan="2" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">Yumizen C1200</td><td colspan="1" rowspan="1">Beckman Coulter AU400</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">10450 ng/mL</td><td colspan="1" rowspan="1">8.0 450 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Sample Matrices</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum, Li-heparin plasma, andEDTA plasma</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">DeviceK191562</td><td colspan="1" rowspan="1">PredicateK012393</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Yumizen C1200 Transferrin</td><td colspan="1" rowspan="1">Roche TINA-QUANTTRANSFERRIN VER.2</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications forUse</td><td colspan="1" rowspan="1">Yumizen C1200 Transferrinreagent is intended for thequantitative in vitro diagnosticdetermination of transferrin inhuman serum and lithium heparinplasma by turbidimetry.Measurement of transferrin levelsaids in the diagnosis ofmalnutrition, acute inflammation,infection, and iron deficiencyanemia.</td><td colspan="1" rowspan="1">The cassette COBAS Integra Tina-quant Transferrin ver.2 containsan in vitro diagnostic reagentsystem intended for use onCOBAS Integra systems for thequantitative immunologicaldetermination of humantransferring in serum and plasma.A transferrin immunological testsystem is a device that consists ofthe reagents used to measure byimmunochemical techniques the</td></tr><tr><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">transferrin (an iron-binding andtransporting serum protein) inserum and plasma. Measurementof transferrin levels aids in thediagnosis of malnutrition, acuteinflammation, infection, and redblood cell disorders, such as irondeficiency anemia.</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Quantitative immunoturbidimetry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">10-520 mg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Matrix</td><td colspan="1" rowspan="1">Serum, Li-heparin plasma</td><td colspan="1" rowspan="1">Serum, plasma</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">ERM-DA470k/IFCC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">Yumizen C1200</td><td colspan="1" rowspan="1">Cobas C701</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">DeviceK191562</td><td colspan="1" rowspan="1">PredicateK060201</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Yumizen C1200 RheumatoidFactor</td><td colspan="1" rowspan="1">Olympus RF Latex Reagent</td></tr><tr><td colspan="1" rowspan="1">General Device Characteristic Similarities</td><td colspan="2" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications forUse</td><td colspan="1" rowspan="1">Yumizen C1200 RheumatoidFactor reagent is intended for thequantitative in vitro diagnosticdetermination of rheumatoidfactor in human serum by latex-enhanced immunoturbidimetricassay.Measurement of rheumatoid factormay aid in the diagnosis ofrheumatoid arthritis.</td><td colspan="1" rowspan="1">Olympus RF Latex SystemReagent for the quantitativedetermination of RheumatoidFactor (RF) in human serum andplasma on OLYMPUS Analyzers.Measurement of rheumatoid factormay aid in the diagnosis ofrheumatoid arthritis.</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Latex enhanced immuno-turbidimetry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Quantitative, competitive</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Cut-off</td><td colspan="1" rowspan="1">14 IU/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">WHO/NIBSC RheumatoidArthritis Serum (64/002)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General Device C</td><td colspan="2" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">Yumizen C1200</td><td colspan="1" rowspan="1">Olympus/Beckman CoulterAU400</td></tr><tr><td colspan="1" rowspan="1">Sample Matrices</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum; lithium heparin plasma;and K2+ EDTA plasma</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">10-120 IU/mL</td><td colspan="1" rowspan="1">5-120 IU/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

• CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures– Third Edition - October 2014   
CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures – Second Edition - June 2012   
• CLSI EP06-A: Evaluation of the Linearity of Quantitative measurement Procedures A Statistical Approach – First Edition – April 2003   
• CLSI C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical laboratory- Third Edition – November 2008   
• CLSI EP25-A: Evaluation of Stability of In Vitro Diagnostic reagents- First EditionSeptember 2009

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

Yumizen C1200 Ferritin: The precision of the Yumizen C1200 Ferritin assay was evaluated on three Yumizen C1200 immunoassay analyzers with one reagent lot. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested with two replicates per run, two runs per day for 20 days on each analyzer $\scriptstyle \mathrm { n = 2 4 0 }$ per sample). The results are summarized below:

<table><tr><td colspan="2" rowspan="1"></td><td colspan="2" rowspan="1">Repeatability</td><td colspan="2" rowspan="1">BetweenRun</td><td colspan="2" rowspan="1">BetweenDay</td><td colspan="2" rowspan="1">BetweenInstrument</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean(ng/mL)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">Sera 1</td><td colspan="1" rowspan="1">29.6</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">7.9</td></tr><tr><td colspan="1" rowspan="1">Sera 2</td><td colspan="1" rowspan="1">50.9</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">5.1</td></tr><tr><td colspan="1" rowspan="1">Sera 3</td><td colspan="1" rowspan="1">172.6</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">Sera 4</td><td colspan="1" rowspan="1">328.6</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">11.8</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">14.2</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="1">Sera 5</td><td colspan="1" rowspan="1">403.2</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">1.4</td></tr><tr><td colspan="1" rowspan="1">Control 1</td><td colspan="1" rowspan="1">47.6</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">4.9</td></tr><tr><td colspan="1" rowspan="1">Control 2</td><td colspan="1" rowspan="1">279.3</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">6.0</td><td colspan="1" rowspan="1">2.1</td></tr></table>

The reproducibility of the Yumizen C1200 Ferritin assay was evaluated on one analyzer with three reagent lots. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested in triplicates per run, two runs per day for five days on each lot $( \mathtt { n } ^ { = 9 0 }$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Within-Lot</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>19.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>11.8</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>34.0</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>51.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>192.3</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>407.4</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>52.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>6.4</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>281.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.6</td></tr></table>

# Yumizen C1200 Transferrin:

The precision of the Yumizen C1200 Transferrin assay was evaluated on three Yumizen C1200 immunoassay analyzers with one reagent lot. Four human sera samples and two levels of Yumizen C1200 Protein Control were tested with two replicates per run, two runs per day for 20 days on each analyzer $( \mathrm { n } { = } 2 4 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>183</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>335</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>3.6</td></tr></table>

The reproducibility of the Yumizen C1200 Transferrin assay was evaluated on one analyzer with three reagent lots. Four human sera sample and two levels of Yumizen C1200 Protein Control were tested in triplicates per run, two runs per day for five days on each lot $( \mathtt { n } ^ { = 9 0 }$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Within-Lot</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>196</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>354</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>341</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>3.0</td></tr></table>

# Yumizen C1200 Rheumatoid Factor:

The precision of the Yumizen C1200 Rheumatoid Factor assay was evaluated on three Yumizen C1200 immunoassay analyzers with one reagent lot. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested with two replicates per run, two runs per day for 20 days on each analyzer $\scriptstyle ( 1 = 2 4 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(IU/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>22.2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>34.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>49.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>70.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>103.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>41.0</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>63.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.5</td></tr></table>

The reproducibility of the Yumizen C1200 Rheumatoid Factor assay was evaluated on one analyzer with three reagent lots. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested in triplicates per run, two runs per day for five days on each lot $\scriptstyle \mathrm { n = 9 0 }$ per sample).

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Within-Lot</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(IU/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>30.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>53.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>70.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>102.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>67.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.2</td></tr></table>

# Yumizen C1200 Ferritin:

Linearity of the Yumizen C1200 Ferritin assay was assessed according to CLSI EP06-A. A high concentration ferritin-spiked human serum sample and a ferritin-depleted human serum were used to create a dilution series covering the measuring range were measured. Sample dilutions were assayed in quadruplicate within a single run and samples within the measuring range were used to determine linearity:

<table><tr><td rowspan=1 colspan=1>Dilution Range(ng/mL)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>13.3426.6</td><td rowspan=1 colspan=1>y=0.99x+3.16</td><td rowspan=1 colspan=1>0.98-1.00</td><td rowspan=1 colspan=1>1.155.18</td><td rowspan=1 colspan=1>0.999</td></tr></table>

Auto-rerun validation study: An auto-rerun study was performed to evaluate the accuracy of the analyzer’s auto dilution function to obtain results for ferritin samples with analyte concentrations above the primary measuring range $( 4 5 0 \mathrm { n g / m L } )$ . Seven samples were used for the study, ranging from $4 7 0 { - } 2 1 6 6 ~ \mathrm { n g / m L }$ . Each sample was manually diluted with a 1:5 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having concentrations up to $2 2 5 0 \mathrm { n g / m L }$ can be run via the rerun function which uses a 1:5 dilution.

Prozone effect: The potential for a prozone effect was evaluated for the ferritin assay. Testing elevated samples did not indicate a prozone effect with concentrations up to $5 0 4 3 ~ \mathrm { n g / m L }$ . A prozone alarm will flag samples $\ge 5 0 4 3 ~ \mathrm { n g / m L }$ .

# Yumizen C1200 Transferrin:

Linearity of the Yumizen C1200 Transferrin assay was assessed according to CLSI EP06-A. A high concentration transferrin-spiked human serum sample and a transferrin-depleted human serum were used to create a dilution series covering the measuring range. Sample dilutions were assayed in quadruplicate within a single run and samples within the measuring range were used to determine linearity. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Dilution Range(mg/dL)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>15.4 461.3</td><td rowspan=1 colspan=1>y=1.05x-5.46</td><td rowspan=1 colspan=1>1.041.07</td><td rowspan=1 colspan=1>-10.24- -0.68</td><td rowspan=1 colspan=1>0.998</td></tr></table>

Auto-rerun validation study: An auto-rerun study was performed to evaluate the accuracy of the analyzer’s auto dilution function to obtain results for transferrin samples with analyte concentrations above the primary measuring range $( 5 2 0 \mathrm { m g / d L } )$ . Seven samples were used for the study, ranging from $5 4 0 { - } 1 4 5 0 \ \mathrm { m g / d L }$ . Each sample was manually diluted with a 1:3 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having higher concentrations up to $1 5 6 0 \mathrm { m g / d L }$ can be run via the rerun function which uses a 1:3 dilution.

Prozone effect: The potential for a prozone effect was evaluated for this assay with spiked native serum samples. Testing elevated samples did not indicate a prozone effect with concentrations up to $4 0 0 0 \mathrm { m g / d L }$ .

# Yumizen C1200 Rheumatoid Factor:

Linearity of the Yumizen C1200 Rheumatoid Factor assay was assessed according to CLSI EP06-A. A high concentration RF-spiked human serum sample and diluent was used to create a dilution series covering the measuring range were measured. Sample dilutions were assayed in quadruplicate within a single run and samples within the measuring range were used to determine linearity. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Dilution Range(IU/mL)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>13.2118.8</td><td rowspan=1 colspan=1>y=0.92x+4.78</td><td rowspan=1 colspan=1>0.910.93</td><td rowspan=1 colspan=1>3.955.60</td><td rowspan=1 colspan=1>0.999</td></tr></table>

Auto-rerun validation study: An auto-rerun study was performed to evaluate the accuracy of the analyzer’s auto dilution functions to obtain results for RF-positive samples with analyte concentrations above the primary measuring range $( 1 2 0 \mathrm { I U / m L } )$ . The Yumizen C1200 Rheumatoid Factor assay includes two flags in the instrument method: an “alarm H” corresponding to a sample that is higher than $1 2 0 \ \mathrm { I U / m L }$ and an “alarm $\mathrm { P } ^ { \prime \prime }$ corresponding to a prozone effect (see below) if the samples is higher than $2 2 9 \mathrm { I U / m L }$ . A 1:4 post-dilution factor will be used if the alarm H is triggered; a 1:10 post-dilution factor will be used if the alarm P is triggered.

Three samples, ranging from $1 3 1 { - } 3 6 4 \ \mathrm { I U / m L }$ , were used to test the accuracy between manual dilutions and automated dilutions triggered by alarm H. Each sample was manually diluted with a 1:4 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having higher concentrations can be run via the rerun function when the alarm H function is triggered.

Four samples, ranging from $5 0 3 \mathrm { - } 1 1 8 0 \mathrm { I U / m L }$ , were used to test the accuracy between manual dilutions and automated dilutions triggered by alarm P. Each sample was manually diluted with a 1:10 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having higher concentrations up to $1 2 0 0 \mathrm { \ I U / m L }$ can be run via the rerun function when the alarm P function is triggered.

Prozone effect: The potential for a prozone effect was evaluated for the Yumizen C1200 Rheumatoid Factor assay. There was a prozone effect with concentrations higher than 143 $\mathrm { I U / m L }$ . Samples with a concentration ${ \scriptstyle > } 2 2 9 \ \mathrm { I U / m L }$ have reaction kinetics that could be interpreted by the instrument as a result within the calibration range of the assay (although still very elevated). The prozone alarm will flag samples with a concentration ${ \scriptstyle > } 2 2 9 \ \mathrm { I U / m L }$ and will be rerun automatically. The package insert describes the prozone flag.

# 3. Analytical Specificity/Interference:

For all three assays, the effect of the presence of endogenous and exogenous interferents in samples was evaluated by testing native unmodified serum pools at two analyte levels with a range of concentration of the substances listed below. Each sample was tested at four concentrations of interferent and with an interferent-free control in four replicates each. The percent recovery for each sample spiked with the interference substance was calculated by comparing its result to that of the corresponding reference sample spiked with an equal volume of the solvent without the interferent. No interference was observed up to the following concentrations for each assay. The results are summarized in the tables below:

# Yumizen C1200 Ferritin:

<table><tr><td rowspan=1 colspan=2>Endogenous</td><td rowspan=1 colspan=4>Exogenous (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Direct Bilirubin</td><td rowspan=1 colspan=1>25.9 mg/dL</td><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>Diltiazem</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>29.5 mg/dL</td><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>65.2</td><td rowspan=1 colspan=1>Ferrous Sulfate</td><td rowspan=1 colspan=1>15.2</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50.1</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>270.4 mg/dL</td><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>Methotrexate</td><td rowspan=1 colspan=1>136.0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>500 IU/mL</td><td rowspan=1 colspan=1>Azithromycin</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>Prednisone</td><td rowspan=1 colspan=1>17.9</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Deferoxamine</td><td rowspan=1 colspan=1>22.4</td><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>—</td><td rowspan=1 colspan=1>Simvastatin</td><td rowspan=1 colspan=1>0.4</td></tr></table>

# Yumizen C1200 Transferrin:

<table><tr><td rowspan=1 colspan=2>Endogenous</td><td rowspan=1 colspan=2>Exogenouss (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Direct Bilirubin</td><td rowspan=1 colspan=1>23.9 mg/dL</td><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20.0</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>43.83 mg/dL</td><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>65.2</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>353.3 mg/dL</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50.1</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>400 IU/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# Yumizen C1200 Rheumatoid Factor:

<table><tr><td rowspan=1 colspan=2>Endogenous</td><td rowspan=1 colspan=2>Exogenous (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Direct Bilirubin</td><td rowspan=1 colspan=1>25.4 mg/dL</td><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20.0</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>31.3 mg/dL</td><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>65.2</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>526.8 mg/dL</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50.1</td></tr></table>

4. Assay Reportable Range: Yumizen C1200 Ferritin: The claimed measuring range is from $1 0 ~ \mathrm { { n g / m L } }$ to $4 5 0 ~ \mathrm { n g / m L }$ . Yumizen C1200 Transferrin: The claimed measuring range is from $1 0 \mathrm { m g / d L }$ to $5 2 0 \mathrm { m g / d L }$ . Yumizen C1200 Rheumatoid Factor: The claimed measuring range is $1 0 \mathrm { m g / L }$ to $1 2 0 \ \mathrm { I U / L }$ .

Traceability:   
Yumizen C1200 Ferritin:   
The Ferritin assay is traceable to the $3 ^ { \mathrm { r d } }$ International Standard for Ferritin, Recombinant NIBSC Code: 94/572.

Yumizen C1200 Transferrin: The Transferrin assay is traceable to ERM-DA470k/IFCC.

Yumizen C1200 Rheumatoid Factor: The RF assay is traceable to WHO/NIBSC Rheumatoid Arthritis Serum (64/002).

Stability:

Real-time shelf-life stability testing supports a shelf-life for unopened reagents stored at the labeling recommendation $[ 2 \mathrm { - } 1 0 ^ { \circ } \mathrm { C }$ (ferritin and RF) or $2 { - } 8 ^ { \circ } \mathrm { C }$ (transferrin)]. On-board reagent stability studies support the on-board storage claims of the Yumizen C1200. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Stability Claims</td><td rowspan=1 colspan=1>Ferritin(ng/mL)</td><td rowspan=1 colspan=1>Transferrin(mg/dL)</td><td rowspan=1 colspan=1>RF(IU/mL)</td></tr><tr><td rowspan=1 colspan=1>Reagent Shelf-lifeif stored as recommended</td><td rowspan=1 colspan=1>18 months</td><td rowspan=1 colspan=1>24 months</td><td rowspan=1 colspan=1>18 months</td></tr><tr><td rowspan=1 colspan=1>Reagent On-board</td><td rowspan=1 colspan=1>2 months</td><td rowspan=1 colspan=1>6 weeks</td><td rowspan=1 colspan=1>1 month</td></tr><tr><td rowspan=1 colspan=1>Serum Sample*</td><td rowspan=1 colspan=1>7 days at 2025°C7 days at 28°C1 year at-20°</td><td rowspan=1 colspan=1>8 days at 2025°C8 days at 48°C6 months at -20°C</td><td rowspan=1 colspan=1>1 day at 2025°C- 8 days at 48°C-3 months at -20°C</td></tr><tr><td rowspan=1 colspan=4>*Sample stability claims in the package insert cite published references.</td></tr></table>

6. Detection Limit:

The detection limits of all three assays were performed according to CLSI EP17-A2. The Limit of Blank (LoB) corresponds to the concentration below which analyte-free samples are found with a probability of $9 5 \%$ . The Limit of Detection (LoD) is determined based on the limit of blank and the standard deviation of low concentration samples. The limit of detection corresponds to the lowest analyte concentration which can be detected (value above the limit of blank with a probability of $9 5 \%$ ). The Limit of Quantitation (LoQ) was defined as the lowest analyte concentration which can be quantified with a total error of $\leq 2 0 \%$ .

# Yumizen C1200 Ferritin:

LoB:

The LoB of the Ferritin assay was determined by assaying one ferritin-depleted serum sample in five replicates per day for four days on three Yumizen instruments. A total of 60 data points per lot were generated; two lots were tested. The LoB for each lot was calculated separately and the higher value determined the LoB. The LoB was defined as $4 . 2 1 ~ \mathrm { n g / m L }$ .

LoD:

The LoD of the Ferritin assay was determined by testing four low analyte serum samples in quadruplicate for four days on one instrument. A total of 64 data points per lot were generated; two lots were tested. The LoD for each lot was calculated separately and the higher value determined the LoD. The LoD was defined as $6 . 3 0 ~ \mathrm { n g / m L }$ .

The LoQ of the Ferritin assay was determined by testing nine low native serum samples in quadruplicate per run, two runs per day, for five days on one instrument. A total of 360 data points per lot were generated; two lots were tested. The LoQ for each lot was calculated separately and the higher value determined the LoQ. The LoQ was defined as $9 . 3 9 \mathrm { n g / m L }$ .

# Yumizen C1200 Transferrin:

$L o B$

The LoB of the Transferrin assay was determined by assaying one blank $\mathrm { ( P B S ^ { + } B S A }$ ) sample in five replicates per day for four days on three Yumizen instruments. A total of 60 data points per lot were generated; two lots were tested. The LoB for each lot was calculated separately and the higher value determined the LoB. The LoB was defined as $0 . 1 0 \mathrm { m g / d L }$ .

LoD:

The LoD of the Transferrin assay was determined by testing four low analyte samples in quadruplicate for four days on one instrument. A total of 64 data points per lot were generated; two lots were tested. The LoD for each lot was calculated separately and the higher value determined the LoD. The LoD was defined as $0 . 2 0 \mathrm { m g / d L }$ .

The LoQ of the Transferrin assay was determined by testing five low native samples in quadruplicate per run, two runs per day, for five days on one instrument. A total of 200 data points per lot were generated; two lots were tested. The LoQ for each lot was calculated separately and the higher value determined the LoQ. The LoQ was defined as $7 . 0 0 \mathrm { m g / d L }$ .

# Yumizen C1200 Rheumatoid Factor:

LoB:

The LoB of the RF assay was determined by testing one diluent sample in five replicates per day for four days on three Yumizen instruments. A total of 60 data points per lot were generated; two lots were tested. The LoB for each lot was calculated separately and the higher value determined the LoB. The LoB was defined as $1 . 5 0 ~ \mathrm { I U / m L }$ .

LoD:

The LoD of the RF assay was determined by testing four low analyte serum samples in quadruplicate for four days on one instrument. A total of 64 data points per lot were generated; two lots were tested. The LoD for each lot was calculated separately and the higher value determined the LoD. The LoD was defined as $4 . 0 7 \ : \mathrm { I U / m L }$ .

The LoQ of the RF assay was determined by testing five low native samples in quadruplicate per run, two runs per day, for five days on one instrument. A total of 200 data points per lot were generated; two lots were tested. The LoQ for each lot was calculated separately and the higher value determined the LoQ. The LoQ was defined as 7.41 IU/mL.

# Detection Limit Summary:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ferritin(ng/mL)</td><td rowspan=1 colspan=1>Transferrin(mg/dL)</td><td rowspan=1 colspan=1>RF(IU/mL)</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>4.21</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.50</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>6.30</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>4.07</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>9.39</td><td rowspan=1 colspan=1>7.00</td><td rowspan=1 colspan=1>7.41</td></tr></table>

7. Assay Cut-Off:

Not applicable for Ferritin and Transferrin.   
RF is expected to be negative in normal healthy population. See Expected Value/Reference Range Section below.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Yumizen C1200 Ferritin:

The sponsor conducted a method comparison of the Yumizen C1200 Ferritin (candidate device) assay and the predicate device. A total of 103 remnant clinical samples covering the measuring range were tested and compared using the Passing-Bablok method. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Range (ng/mL)</td><td rowspan=1 colspan=1>12.2440.7 ng/mL (Predicate, X)16.7413.0 ng/mL (Assay, Y)</td></tr><tr><td rowspan=1 colspan=1>Slope(95th CI)</td><td rowspan=1 colspan=1>0.91(0.910.92)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95th CI)</td><td rowspan=1 colspan=1>2.10(0.983.30)</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.999</td></tr></table>

# Yumizen C1200 Transferrin:

The sponsor conducted a method comparison of the Yumizen C1200 Transferrin (candidate device) assay and the predicate device. A total of 115 remnant clinical samples covering the measuring range were tested and compared using the Passing-Bablok method. The results are summarized below:

<table><tr><td colspan="1" rowspan="1">Parameter</td><td colspan="1" rowspan="1">Result</td></tr><tr><td colspan="1" rowspan="1">Range (mg/dL)</td><td colspan="1" rowspan="1">43500 mg/dL (Predicate, X)37481 mg/dL (Candidate, Y)</td></tr><tr><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">0.946</td></tr><tr><td colspan="1" rowspan="1">(95th CI)</td><td colspan="1" rowspan="1">(0.9260.964)</td></tr><tr><td colspan="1" rowspan="1">Intercept(95th CI)</td><td colspan="1" rowspan="1">0.006(-0.0230.055)</td></tr><tr><td colspan="1" rowspan="1">CorrelationCoefficient</td><td colspan="1" rowspan="1">0.993</td></tr></table>

# Yumizen C1200 Rheumatoid Factor:

The sponsor conducted a method comparison of the Yumizen C1200 Rheumatoid Factor (candidate device) assay and the predicate device. A total of 113 anonymous samples collected from a blood bank covering the entire measuring range were tested and compared using the Passing-Bablok method:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Range (mg/dL)</td><td rowspan=1 colspan=1>16.9119.0 IU/mL (Predicate, X)16.8118.8 IU/mL (Candidate, Y)</td></tr><tr><td rowspan=1 colspan=1>Slope(95th CI)</td><td rowspan=1 colspan=1>1.01(1.001.03)</td></tr><tr><td rowspan=1 colspan=1>Intercept(95th CI)</td><td rowspan=1 colspan=1>-1.11(-1.70  -0.23)</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.992</td></tr></table>

# 2. Matrix Comparison:

Only serum is indicated for the Yumizen C1200 Ferritin and Rheumatoid Factor assays.

For the Yumizen C1200 Transferrin assay, a study comparing 59 paired serum and lithium heparin plasma samples demonstrated equivalence between the matrices:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>Pearson r</td></tr><tr><td rowspan=1 colspan=1>Li-heparin vs. Serum</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>193379</td><td rowspan=1 colspan=1>0.97(0.930.99)</td><td rowspan=1 colspan=1>0.05(-0.02- 0.14)</td><td rowspan=1 colspan=1>0.995</td></tr></table>

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

D Clinical Cut-Off: Not applicable

# E Expected Values/Reference Range:

Yumizen C1200 Ferritin:

The sponsor validated female and male ferritin reference ranges cited in a reference1 . Samples from a blood bank were used: 50 female samples and 95 male samples to validate a reference range of $1 0 { - } 1 2 0 \ \mathrm { n g / m L }$ for women and $2 0 { - } 2 5 0 \ \mathrm { n g / m L }$ for men.

# Yumizen C1200 Transferrin:

The sponsor validated transferrin reference ranges cited in a reference2 . Samples $( \mathrm { n } { = } 8 5$ , 28 female and 57 males) from a blood bank were used and validate a reference range of 200–360 $\mathrm { m g / d L }$ .

# Yumizen C1200 Rheumatoid Factor:

The sponsor validated RF reference ranges cited in a reference3 . Sixty samples from a blood bank were used and validate a reference range of ${ < } 1 4 \ \mathrm { I U / m L }$ .

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.